[Use of platelet antiaggregating agents in acute coronary syndromes].
Nowadays, it is known that platelets are the main agents involved in the pathogenesis of acute coronary syndromes, and the fact that aspirin is a weak antiplatelet agent has led to an intensive research in antiplatelet drugs in the last years. The medical literature from the last decade contains many studies on the use of platelet IIb/IIIa receptor blockers in different clinical settings. Agents that block the IIb/IIIa platelet receptor have shown to be useful in improving prognosis of patients with acute coronary syndromes (ACS), especially in those studies of percutaneous coronary revascularization procedures. However, their potential risk of causing bleeding and high cost have prevented applied universal and routine application. There are some aspects, such as correct dosage, optimal duration of treatment, and direct comparison of the efficacy of different types of IIb/IIIa blockers, that not have not been resolved yet. On the other hand, oral IIb/IIIa antagonists have not exceeded the efficacy of aspirin. Finally, it is necessary to identify those patients that will obtain the most benefit from this treatment to avoid unnecessary risks and costs. Therefore, it is very important, for the nurse to have the necessary knowledge on the therapeutic effect and use of this antiplatelets therapy, to be able to identify in time any complication that night increase the risk and in danger the patient's life.
Torres Peláez
María de Lourdes
Mde L
Unidad Coronaria, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D. F.
Santiago Arana
Catalina
C
D000208:Acute Disease; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013577:Syndrome
D010975:Platelet Aggregation Inhibitors